Medscape Conference Coverage, based on selected sessions at the:

Heart Failure Society of America (HFSA) 12th Annual Scientific Meeting

September 21 - 24, 2008; Toronto, Ontario, Canada

This activity is not sanctioned by, nor a part of, the Heart Failure Society of America. Conference news does not receive grant support and is produced independently.

Conference News

  • Genetic Testing to Guide Heart Failure Therapy

    Is cardiovascular care poised to enter the brave new world of pharmacogenomics? A test for a pair of genetic markers seems to distinguish heart-failure patients who are likely or unlikely to respond to a beta blocker now under FDA review.
    Heartwire, October 22, 2008
  • No Outcomes Deficit With Weekend HF Admission

    The finding is contrary to what has been found for hospitalizations due to some other CV disorders.
    Heartwire, October 3, 2008
  • Heart-Failure Subspecialty Board Certification

    The certification is expected to encompass the management of patients with implantable defibrillators and biventricular pacemakers, although not device insertions.
    Heartwire, September 30, 2008
  • Cardiac and Renal Effects of SLV320

    The agent modestly reduced pulmonary capillary wedge pressures at the highest doses, had a weak diuretic effect, and improved renal-function measures. More research into the effects of A1-receptor antagonists on morbidity and mortality are still needed, say investigators.
    Heartwire, September 29, 2008
  • Myosin-Activating Agent: Please Don't Call it an "Inotrope"

    It's still in early-phase studies, but researchers hope the drug, which seems to prolong systole and enhance cardiac output without raising myocardial oxygen demand, will offer the benefits of conventional inotropic agents without their dark side.
    Heartwire, September 26, 2008
  • Once-a-Day Carvedilol "Noninferior" to Twice-Daily Version in Heart Failure

    Some believe once-daily carvedilol for heart failure will improve compliance and therefore outcomes, compared with the twice-daily version; others wonder whether noninferiority is worth the extra cost.
    Heartwire, September 25, 2008

    Fluid indices crossing a predefined threshold significantly increased the risk of subsequent heart-failure decompensation, shortness of breath, peripheral edema, and fatigue, suggesting impedance data can help stratify patients at risk for worsening heart failure, report investigators.
    Heartwire, September 24, 2008
  • Thyroid Hormone Analog for Heart Failure

    The phase 2 study was stopped early because the compound worsened heart-failure symptoms, although it did have a positive effect on weight and lipid profiles.
    Heartwire, September 24, 2008
  • SADHART-CHF: Nurse Intervention Impresses for Depression in HF

    The trial, underpowered for clinical outcomes, failed even to demonstrate that sertraline alleviated depression; observers attribute the finding to the unique nonpharmacologic therapy actively treated patients and controls both received.
    Heartwire, September 23, 2008
  • Continuous Aortic Flow Therapy

    Chronic heart-failure patients with nonischemic etiology and without kidney dysfunction or severe N-terminal pro-brain-natriuretic peptide expression appear to benefit from the device. The data are hypothesis generating at this point, say investigators, and decisions will need to be made about where to go next with the aortic flow therapy.
    Heartwire, September 22, 2008

The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.

The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the Heart Failure Society of America. These materials and the related activity are not sanctioned by the Heart Failure Society of America or the commercial supporter of the conference and do not constitute an official part of that conference.